Pioneering perspectives
Prof. Chi Kong Li, MD, Chinese University of Hong Kong
Pioneering perspectives
"We were so excited...we could find a new way to help these patients who probably have little chance of cure."
Prof. Chi Kong Li, MD, Chinese University of Hong Kong
Further discussion
Point-of-care manufacturing regulations: collaborative efforts to ensure safe therapies
As a specialist in pediatric hematology and oncology at the Chinese University of Hong Kong (CUHK), Professor Chi Kong Li has dedicated his career to transforming the lives of children battling leukemia and undergoing stem cell transplants. In recent years, his focus has shifted to the cutting-edge field of cellular therapy which shows great promise in treating leukemia.
Although these novel therapies have demonstrated significant success in clinical trials, centralized manufacturing, amongst other factors, provide certain limitations.1 This process involves complex logistics and high costs, resulting in long wait times and limited accessibility, especially in countries that are difficult to reach or not within the scope of major pharmaceutical companies.2 Observing these challenges and being confronted with the plight of his patients, Professor Li and his team explored options to make these life-saving treatments more accessible.
Point-of-care (PoC) cell manufacturing, a decentralized approach where cell therapies are produced locally at or near hospitals, has the potential for faster production and administration at treatment sites, reducing costs and increasing patient access to treatment.2,3 Professor Li recalls, “We were so excited at that time, we could find a new way to help these patients who probably have little chance of cure.”
To make this approach a reality, however, significant investment in technology, training, and regulatory alignment is needed.4 Collaborative efforts between PoC centers, clinicians, industry partners supporting with tools and technologies, and health authorities, are essential to improve access to CAR T cell therapies and to ensure the safe and effective delivery of life-saving therapies to patients.4
Professor Li highlights that, “regulatory authorities are very cautious in accepting some new procedures”, and that overcoming these hurdles are especially challenging for hospitals, which are often new to this field and lack the necessary resources, capacities, and knowledge.
As Professor Li emphasizes, a huge advantage of the CliniMACS Prodigy® Platform is the automation of various steps in cell therapy manufacturing, reducing manual processes, and minimizing the risk of contamination. Its adaptability to different manufacturing procedures and its closed, GMP-compliant design boost regulatory confidence. Using the CliniMACS Prodigy Platform supports efficiency, scalability, and accessibility of cell and gene therapies, making it a valuable tool in the field of Advanced Therapy Medicinal Products (ATMP) manufacturing.
Despite some hurdles, pre-dominantly brought on by the COVID-19 pandemic, Professor Li and his team succeeded in establishing PoC manufacturing at the Advanced Therapy Products (ATP) Good Manufacturing Practice (GMP) Centre, led by CUHK in collaboration with the Hong Kong Science and Technology Parks Corporation (HKSTP). This initiative has achieved a remarkable milestone as the first "made-in-Hong Kong" anti-CD19 CAR T cell therapy – a powerful weapon against blood cancers.5
"We have the duty to save the life of the patient."
Prof. Chi Kong Li, MD, Chinese University of Hong Kong